Multicenter Phase 1b/2a Clinical Trial of Radioprotectant BIO 300 Oral Suspension for Patients with Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy (vol 118, pg 404, 2023)

被引：0
|
作者：
Simone II, C. B.
Serebrenik, A. A.
Gore, E. M.
机构：
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 119卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2024.02.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1029 / 1029
页数：1
相关论文
共 50 条
  • [21] A PHASE 1B STUDY OF AMG 655 IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
    Paz-Ares, L.
    Torres, J. M. Sanchez
    Diaz-Padilla, I.
    Links, M.
    Reguart, N.
    Boyer, M.
    Wiezorek, J.
    Sabin, T.
    Hsu, M.
    Van Meerbeeck, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 161 - 161
  • [22] A phase II study of concurrent chemoradiotherapy with cisplatin and oral S-1, followed by surgery for locally advanced non-small cell lung cancer.
    Tsuchiya, Tomoshi
    Nakamura, Yoichi
    Hayashi, Nobuyuki
    Matsumoto, Keitaro
    Miyazaki, Takuro
    Tabata, Kazuhiro
    Fukuoka, Junya
    Yamasaki, Naoya
    Nagayasu, Takeshi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Results From a Phase 1b Trial
    Wong, Deborah J.
    Bauer, Todd M.
    Gordon, Michael S.
    Bene-Tchaleu, Fabiola
    Zhu, Jing
    Zhang, Xiaosong
    Cha, Edward
    CLINICAL LUNG CANCER, 2022, 23 (03) : 273 - 281
  • [24] A Phase 1b/2 Study of Atezolizumab With or Without Daratumumab in Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
    Pillai, R.
    Ramalingam, S.
    Paz-Ares, L.
    Thayu, M.
    Watson, P.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2288 - S2288
  • [25] The impact of right ventricular function on prognosis in patients with stage III non-small cell lung cancer after concurrent chemoradiotherapy (vol 35, pg 1009, 2019)
    Chen, Lu
    Huang, Jingjuan
    Wu, Weihua
    Ta, Shengjun
    Xie, Xiaoyi
    INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING, 2019, 35 (09): : 1671 - 1671
  • [26] PHASE I STUDY EVALUATING ORAL PANOBINOSTAT CONCURRENTLY WITH RADIOTHERAPY OR CHEMORADIOTHERAPY IN INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS
    Takhar, H.
    Singhal, N.
    Gowda, R.
    Penniment, M.
    Brown, M. P.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 66 - 66
  • [27] Preoperative chemoradiotherapy followed by surgery for stage IIIB non-small cell lung cancer (NSCLC). A multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK)
    Stupp, Roger
    Kann, Roger
    Zouhair, Abderrahim
    Mayer, Michael
    Thierstein, Sandra
    Stahel, Rolf
    Betticher, Daniel
    Balmer, Majno Sabine
    Ris, Hans-Beat
    Pless, Miklos
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S367 - S368
  • [28] A Phase 1b/2, Open-Label Study of Bintrafusp Alfa with Chemotherapy in Patients with Stage IV Non-Small Cell Lung Cancer
    Barlesi, F.
    Hiret, S.
    Rolfo, C.
    Grenga, I.
    Koenig, A.
    Vugmeyster, Y.
    Horn, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S27 - S27
  • [29] Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study
    Takeya Sugimoto
    Daichi Fujimoto
    Yuki Sato
    Motohiro Tamiya
    Takashi Yokoi
    Akihiro Tamiya
    Shunichiro Iwasawa
    Akito Hata
    Junji Uchida
    Yasushi Fukuda
    Satoshi Hara
    Masaki Kanazu
    Katsuya Hirano
    Masaki Kokubo
    Nobuyuki Yamamoto
    Investigational New Drugs, 2021, 39 : 853 - 859
  • [30] Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study
    Sugimoto, Takeya
    Fujimoto, Daichi
    Sato, Yuki
    Tamiya, Motohiro
    Yokoi, Takashi
    Tamiya, Akihiro
    Iwasawa, Shunichiro
    Hata, Akito
    Uchida, Junji
    Fukuda, Yasushi
    Hara, Satoshi
    Kanazu, Masaki
    Hirano, Katsuya
    Kokubo, Masaki
    Yamamoto, Nobuyuki
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (03) : 853 - 859
12345